Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Septal mass reduction is beneficial for hypertrophic obstructive cardiomyopathy (HOCM) patients with severe left ventricular outflow (LVOT) gradient and symptoms, with surgical myectomy or alcohol septal ablation (ASA) currently recommended in selected patients. Radiofrequency (RF) ablation of hypertrophied septum has been published as a novel method to alleviate LVOT obstruction in small populations. This study aims to investigate factors influencing clinical outcomes of radiofrequency septum ablation. In this study, 20 patients with HOCM who underwent endocardial ablation were included. Echocardiography and cardiac MRI (CMR) data was collected and analyzed pre- and (or) post- procedure. Nineteen patients underwent ablation successfully, while ablation was aborted in one patient with prior RBBB due to transient complete atrioventricular block (AVB). After 6 months of follow-up, NYHA heart functional class improved from III (2 - 3) to II (1 - 2) ( < 0.001), and resting LVOT gradient was significantly reduced (87.6 ± 29.5 mmHg vs. 48.1 ± 29.7, < 0.001). LVOT gradient reduction was significantly higher in patients with limited basal septal hypertrophy (60.9 ± 8.3 vs. 27.9 ± 7.1, = 0.01), shorter anterior mitral leaflet (56.1 ± 6.4 vs. 20.4 ± 5.0, < 0.01), and normally positioned papillary muscle (36.9 ± 7.1 vs. 75.0 ± 6.3, < 0.05). Endocardial septal ablation appears to be a safe and effective procedure for alleviating LVOT gradient in patients with HOCM, especially in those with limited basal septal hypertrophy, shorter anterior mitral leaflet, and normal positioned papillary muscle.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635065 | PMC |
| http://dx.doi.org/10.3389/fcvm.2021.743044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of centre experience on complete clinical and haemodynamic response after alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
Int J Cardiol
September 2025
Department of Demography and Geodemography, Faculty of Science, Charles University, Prague, Czech Republic.
Background: Alcohol septal ablation (ASA) is an established therapy for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) in patients unresponsive to medical treatment. However, comprehensive assessment of ASA outcomes remains challenging. This study aimed to evaluate the impact of institutional experience and patient characteristics on achieving complete clinical and haemodynamic response (CCHR), a novel composite outcome integrating long-term symptomatic, haemodynamic, safety, and major clinical endpoints, including survival and resuscitation.
View Article and Find Full Text PDFMavacamten effectively reduces > 100 mmHg left ventricular outflow tract gradients As early as one week of treatment in obstructive hypertrophic cardiomyopathy.
Int J Cardiol
September 2025
Division of Non-Invasive Cardiology, Cardiology Centre, Department of Medicine, University of Szeged, Hungary. Electronic address:
Background: Real-world data on the efficacy of mavacamten, indicated for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), are relatively scarce, particularly in patients with extreme left ventricular outflow tract (LVOT) gradients and concerning its short-term effects.
Patients/methods: We investigated a cohort of twenty-five oHCM patients [15 men (60 %), mean age: 55 ± 11 years], with a resting or provoked LVOT gradient of >100 mmHg, receiving mavacamten treatment. Patients underwent a complete standard and 2D-speckle tracking echocardiographic examination after one week (W1) of treatment initiation and at subsequent four-week intervals.
Mitral Transcatheter Edge-to-Edge Repair in Symptomatic Hypertrophic Cardiomyopathy: A Systematic Review.
Catheter Cardiovasc Interv
September 2025
Department Interventional Cardiology, University of Miami, Coral Gables, Florida, USA.
Background: Hypertrophic cardiomyopathy (HCM) with left ventricular outflow tract (LVOT) obstruction poses significant clinical challenges. Although septal reduction therapy (SRT) is the first treatment strategy after medical therapy, mitral transcatheter edge-to-edge repair (M-TEER) has been reported in the emerging literature to alleviate the LVOT obstruction related to mitral regurgitation (MR) and systolic anterior motion (SAM).
Aims: In this article, we aim to evaluate the efficacy and safety of M-TEER in managing symptomatic HCM.
Background: Mavacamten is commercially approved for use in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients. This study evaluated its real-world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy (SRT) in oHCM patients treated at a multi-hospital referral center.
Methods: We included 244 oHCM patients (mean age 64 years, 57% female, 21% with atrial fibrillation, 51% New York Heart Association [NYHA] Class III, 82% on beta-blockers) treated with mavacamten for ≥3 months (171 for ≥12 months).
Left ventricular outflow tract obstruction appearing in remote period of right ventricular septal pacing in patient with left ventricular septal bulge.
BMJ Case Rep
August 2025
Department of Cardiology, National Hospital Organisation Kagoshima Medical Center, Kagoshima, Japan.
A woman in her 70 s presented with fatigue and dyspnoea during exertion. Six years ago, she had been implanted with a dual chamber pacemaker with the lead placement at the high septal site of the right ventricle. Echocardiography demonstrated the presence of the previously detected left ventricular septal bulge along with a newly observed systolic turbulent mosaic at left ventricular outflow tract (LVOT) and a systolic anterior motion (SAM) of the mitral valve.
View Article and Find Full Text PDF